Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
This early-stage study tests a new radioactive drug combined with standard chemotherapy and targeted radiation. It aims to prepare adults with high-risk blood cancers for a successful donor stem cell transplant by safely destroying remaining cancer cells.
Adults diagnosed with certain high-risk blood cancers, such as acute leukemias or myelodysplastic syndrome, may be eligible. Participants must be able to carry out normal daily activities and meet specific age and medical history requirements.
Participants will receive the new targeted radioactive treatment along with standard chemotherapy and precise radiation before undergoing a donor stem cell transplant. The study also involves routine tests like blood draws, bone marrow checks, and heart scans to monitor safety and progress.
This study is currently recruiting participants in Duarte, California, United States.
- 1Tests a new radioactive drug combined with transplant preparation treatments
- 2Aims to improve outcomes for patients with high-risk blood cancers
- 3Involves getting a donor stem cell transplant along with careful health monitoring
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.